Cargando…
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
OBJECTIVES: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our objective was to update the data in a living systematic review of the literature concerning the efficacy and toxicity of t...
Autores principales: | Tleyjeh, Imad M., Kashour, Zakariya, Riaz, Muhammad, Hassett, Leslie, Veiga, Viviane C., Kashour, Tarek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076756/ https://www.ncbi.nlm.nih.gov/pubmed/33915284 http://dx.doi.org/10.1016/j.cmi.2021.04.019 |
Ejemplares similares
-
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
por: Tleyjeh, Imad M., et al.
Publicado: (2021) -
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
por: Kashour, Tarek, et al.
Publicado: (2021) -
Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
por: Kashour, Zakariya, et al.
Publicado: (2021) -
It is time to drop hydroxychloroquine from our COVID-19 armamentarium
por: Kashour, Tarek, et al.
Publicado: (2020) -
Letter About: Risk Factors for Mortality in Patients with COVID-19 in New York City
por: Tleyjeh, Imad M., et al.
Publicado: (2021)